6:19 PM
 | 
Oct 06, 2015
 |  BC Extra  |  Company News

FDA denies Otsuka petition, approves Alkermes' Aristada

Alkermes plc (NASDAQ:ALKS) fell $1.27 to $58.50 amid a wider biotech sell-off on Tuesday, a day after FDA approved the company's Aristada aripiprazole lauroxil to treat schizophrenia. The drug is an injectable, extended-release formulation of aripiprazole using LinkeRx technology (see BioCentury Extra, Oct. 5).

FDA also...

Read the full 231 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >